CWA
VRTX icon

Clearview Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Clearview Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50
Closed -$17.6K – 631
2023
Q2 		$17.6K Hold
50
– – 0.02% 291
2023
Q1 		$15.8K Hold
50
– – 0.02% 303
2022
Q4 		$14.4K Hold
50
– – 0.01% 292
2022
Q3 		$14K Hold
50
– – 0.01% 300
2022
Q2 		$14K Hold
50
– – 0.01% 321
2022
Q1 		$13K Sell
50
-15
-23% -$3.56K 0.01% 352
2021
Q4 		$14K Hold
65
– – 0.01% 373
2021
Q3 		$12K Hold
65
– – 0.01% 396
2021
Q2 		$13K Sell
65
-138
-68% -$28.9K 0.01% 388
2021
Q1 		$44K Hold
203
– – 0.03% 240
2020
Q4 		$48K Buy
+203
New +$46.6K 0.03% 201

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return